1. Home
  2. BNRG vs AZTR Comparison

BNRG vs AZTR Comparison

Compare BNRG & AZTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Brenmiller Energy Ltd

BNRG

Brenmiller Energy Ltd

HOLD

Current Price

$0.76

Market Cap

4.7M

Sector

N/A

ML Signal

HOLD

Logo Azitra Inc

AZTR

Azitra Inc

HOLD

Current Price

$0.30

Market Cap

4.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BNRG
AZTR
Founded
2012
2014
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.7M
4.2M
IPO Year
2022
2023

Fundamental Metrics

Financial Performance
Metric
BNRG
AZTR
Price
$0.76
$0.30
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$4.00
AVG Volume (30 Days)
67.6K
314.3K
Earning Date
09-30-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$387,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
843.90
N/A
52 Week Low
$0.80
$0.30
52 Week High
$15.30
$4.33

Technical Indicators

Market Signals
Indicator
BNRG
AZTR
Relative Strength Index (RSI) 24.48 34.09
Support Level $1.08 $0.34
Resistance Level $1.16 $0.39
Average True Range (ATR) 0.09 0.03
MACD -0.02 0.01
Stochastic Oscillator 2.84 8.36

Price Performance

Historical Comparison
BNRG
AZTR

About BNRG Brenmiller Energy Ltd

Brenmiller Energy Ltd is a technology company that develops, produces, markets, and sells thermal energy storage. The technology of the company allows electrification and decarbonization of the industrial industry sector for integration with renewable energy sources and further reduction of carbon emissions.

About AZTR Azitra Inc

Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.

Share on Social Networks: